Anzeige
Mehr »
Freitag, 12.06.2026 - Börsentäglich über 12.000 News
Diese Aktie anschauen - Kurz vor Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DTRX | ISIN: US92854B1098 | Ticker-Symbol: U5P
Tradegate
09.06.26 | 19:22
0,965 Euro
-1,03 % -0,010
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVANI MEDICAL INC Chart 1 Jahr
5-Tage-Chart
VIVANI MEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9450,98017:51
0,9550,99017:50

Aktuelle News zur VIVANI MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
VIVANI MEDICAL Aktie jetzt für 0€ handeln
04.06.Vivani Medical, Inc. - 8-K, Current Report1
13.05.Vivani Medical, Inc. - 8-K, Current Report1
13.05.Vivani Medical, Inc. - 10-Q, Quarterly Report1
13.05.Vivani Medical, Inc.: Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update152Initiation of SLIM-1 clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents...
► Artikel lesen
27.03.Vivani completes first-in-human study of GLP-1 implant2
26.03.Vivani Medical, Inc. - 8-K, Current Report1
26.03.Vivani Medical, Inc. - 10-K, Annual Report1
26.03.Vivani Medical GAAP EPS of -$0.43 misses by $0.012
26.03.Vivani Medical, Inc.: Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update659Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under...
► Artikel lesen
29.01.Vivani Medical, Inc.: Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026339Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial...
► Artikel lesen
27.01.Vivani Medical, Inc. Announces Closing of Common Stock Offering4
27.01.Vivani Medical, Inc. - 8-K, Current Report3
26.01.Vivani Medical prices common stock offering1
26.01.Vivani Prices Common Stock Offering At $1.48/Shr-
26.01.Vivani Medical prices $4.5 million stock offering at $1.48 per share3
26.01.Vivani Medical, Inc. Announces Pricing of Common Stock Offering1
22.01.Vivani Medical, Inc.: Vivani Subsidiary Cortigent to Present Orion System's Advanced Brain Implant Technology in Poster Session at NANS 20261
13.11.25Vivani Medical, Inc.: Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results269Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase...
► Artikel lesen
03.10.25Vivani Medical, Inc.: Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off387ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
► Artikel lesen
17.09.25Vivani Medical, Inc.: Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders305Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1